Study guide

14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis

Key Takeaways Explain This Topic AI

Estrogen stimulates hepatic thyroxine-binding globulin (TBG) synthesis, expanding the circulating total T4 and T3 pool, while first-trimester hCG shares structural alpha-subunit homology with TSH, exerting weak agonism that physiologically suppresses serum TSH during weeks 8–14.

Primary hypothyroidism is predominantly caused by Hashimoto thyroiditis (positive anti-TPO antibodies); clinical sequelae in women include menorrhagia, anovulatory infertility, and galactorrhea/amenorrhea triggered by elevated hypothalamic TRH stimulating pituitary lactotrophs.

Levothyroxine (full replacement ~1.6 mcg/kg/day) must be taken on an empty stomach with water 30–60 minutes before breakfast, separated from calcium, iron, and prenatal vitamins by at least 4 hours, with TSH monitored every 6–8 weeks during dose titration.

Maternal thyroid hormone is indispensable for first-trimester fetal neurocognitive development; women with pre-existing hypothyroidism must preemptively increase levothyroxine dosage by 20%–30% (two additional doses weekly) immediately upon a missed period or positive pregnancy test, targeting the lower half of the trimester-specific TSH range (or <2.5 mIU/L when no local range exists; ATA 2017).

Hyperthyroidism in pregnancy requires propylthiouracil (PTU) in the first trimester to avoid methimazole embryopathy (aplasia cutis congenita, choanal atresia), with many clinicians switching to methimazole after the first trimester to limit PTU hepatotoxicity; postpartum thyroiditis is a destructive, biphasic process (hyperthyroid followed by hypothyroid) where thionamides are ineffective.

Last updated: October 2026

Thyroid Physiology Across the Female Lifespan & Pregnancy

Thyroid homeostasis is intimately linked to female reproductive endocrinology. Estrogen, human chorionic gonadotropin (hCG), and gestational hemodynamics produce profound endocrine adaptations:

1. Estrogen & Thyroxine-Binding Globulin (TBG)

Circulating estrogen—whether endogenous during pregnancy or exogenous via oral contraceptives or menopausal hormone therapy—stimulates hepatic TBG synthesis and slows TBG clearance through sialylation. Serum TBG concentrations double within weeks of estrogen exposure. As TBG binds circulating free thyroxine (T4) and triiodothyronine (T3), the hypothalamic-pituitary-thyroid (HPT) axis increases hormone synthesis until binding sites saturate and free hormone levels normalize. Consequently, total T4 and total T3 concentrations increase by roughly 50% , whereas free T4 (FT4) and free T3 (FT3) remain normal in euthyroid women. Total hormone measurements cannot be used to assess thyroid status in hyperestrogenic states.

2. Human Chorionic Gonadotropin (hCG) Cross-Reactivity

hCG shares an identical 92-amino acid α-subunit with TSH, LH, and FSH, with homology in its β-subunit. At peak concentrations between 8 and 14 weeks , circulating hCG binds to and weakly stimulates the thyroidal TSH receptor. This stimulates thyroid hormone secretion, which exerts negative feedback on pituitary thyrotrophs, producing a physiologic suppression of serum TSH (often dropping <0.4 mIU/L or <0.1 mIU/L in up to 15% of normal pregnancies, particularly in multifetal gestations or hyperemesis gravidarum).

3. Renal Iodine Clearance & Gestational Demands

During pregnancy, marked renal hyperfiltration increases urinary iodide excretion, while the feto-placental unit actively extracts maternal iodide. The WHO and American Thyroid Association (ATA) recommend that pregnant and lactating women ingest 250 mcg of elemental iodine daily , typically achieved with prenatal vitamins containing 150 mcg of potassium iodide.

Primary Hypothyroidism & Hashimoto Thyroiditis

Primary hypothyroidism occurs when intrinsic thyroid pathology impairs hormone synthesis, driving compensatory pituitary TSH hypersecretion.

Etiology & Pathogenesis

Hashimoto Thyroiditis (Chronic Autoimmune Lymphocytic Thyroiditis): The predominant etiology in iodine-sufficient regions. Pathophysiologically characterized by cell-mediated destruction: CD4+ and CD8+ T lymphocytes infiltrate thyroid follicles, accompanied by oxyphilic (Hürthle) cell metaplasia, follicular atrophy, and interstitial fibrosis.

Serologic Biomarkers: Serum anti-thyroid peroxidase (anti-TPO) antibodies are positive in >90% to 95% of patients; anti-thyroglobulin (anti-Tg) antibodies are present in 60% to 80%.

Clinical Manifestations & Gynecologic Sequelae

Systemic features reflect metabolic slowing: fatigue, cold intolerance, weight gain, constipation, dry skin, diffuse alopecia, periorbital myxedema, hoarseness, carpal tunnel syndrome, and delayed relaxation ("hung-up") deep tendon reflexes.

Menstrual Dysfunction: Causes menorrhagia (heavy menstrual bleeding) early in the course due to impaired estrogen clearance and clotting factor deficits, progressing to oligomenorrhea or secondary amenorrhea as anovulation develops.

TRH-Mediated Hyperprolactinemia: The hypothalamus hypersecretes Thyrotropin-Releasing Hormone (TRH) to stimulate the failing thyroid. TRH directly stimulates pituitary lactotrophs, causing hyperprolactinemia , galactorrhea , and hypogonadotropic anovulatory subfertility.

Diagnostic Laboratory Profiles

Primary Overt Hypothyroidism: Elevated serum TSH ( >4.0–4.5 mIU/L ) accompanied by low free T4 ( <0.8 ng/dL ).

Subclinical Hypothyroidism: Elevated serum TSH ( >4.0–4.5 mIU/L ) with a normal free T4 concentration. Progression to overt failure occurs at ~5% annually, accelerated by positive anti-TPO titers.

Pharmacotherapy: Levothyroxine Management

Synthetic levothyroxine (LT4) is the first-line therapy of choice for hypothyroidism.

Dosing Principles & Absorption Rules

Full Replacement Dose: Approximately 1.6 mcg/kg/day based on ideal body weight for young, healthy non-pregnant adults without comorbidities (typically 75 to 125 mcg daily).

Elderly Patients & Coronary Artery Disease: Initiate cautiously at 25 to 50 mcg daily and titrate slowly by 12.5 to 25 mcg increments every 6 to 8 weeks to avoid cardiac ischemia or tachyarrhythmias.

Fasting Requirement: Take once daily with water on an empty stomach , strictly 30 to 60 minutes before breakfast , or at bedtime 3 to 4 hours after the last meal .

The 4-Hour Separation Rule: Polyvalent cations and acid suppressors dramatically reduce levothyroxine bioavailability. Separate levothyroxine administration by at least 4 hours from calcium carbonate , ferrous sulfate (iron) , prenatal vitamins, aluminum/magnesium antacids, sucralfate, and bile acid sequestrants.

Monitoring & Titration

Because levothyroxine has a ~7-day half-life, steady-state concentrations require 4 to 6 weeks. Recheck serum TSH 6 to 8 weeks after initiating therapy or adjusting the dose. Once stable, monitor TSH annually.

Hypothyroidism in Pregnancy: Maternal-Fetal Safeguards

During the first 10 to 12 weeks of gestation, the embryo relies 100% on transplacental passage of maternal T4 for cerebral cortical neurogenesis and neuronal migration.

Obstetric Risks & Trimester Targets

Untreated maternal hypothyroidism causes irreversible neurocognitive deficits (loss of offspring IQ points), congenital cretinism, spontaneous miscarriage, preeclampsia, placental abruption, and low birth weight.

TSH Targets: The 2017 ATA guideline targets the lower half of the trimester-specific reference range in treated women, or <2.5 mIU/L when no local range is available. For diagnosing hypothyroidism without a local range, the first-trimester upper limit is about 4.0 mIU/L .

Empirical Dose Escalation Protocol: Women with pre-existing hypothyroidism must be instructed to immediately increase their levothyroxine dose by 20% to 30% upon a missed period or positive pregnancy test. This is achieved by taking two additional tablets per week (e.g., doubling the dose on two designated days, such as Mondays and Thursdays).

Gestational Surveillance: Order serum TSH and free T4 immediately upon pregnancy confirmation, and recheck TSH every 4 weeks throughout the first half of pregnancy .

  • Hyperthyroidism & Thyrotoxicosis
  • Etiologies & Diagnostics

Graves Disease: Circulating thyroid-stimulating immunoglobulins (TSI) continuously activate TSH receptors. Hallmarks: diffuse toxic goiter with vascular bruit, Graves ophthalmopathy (exophthalmos, proptosis), and pretibial myxedema .

Toxic Nodular Goiter & Subacute Thyroiditis: Autonomous nodules or post-viral inflammatory follicular destruction.

Diagnostic Profile: Suppressed TSH ( <0.1 mIU/L ) with elevated free T4 and/or free T3. Radioactive Iodine Uptake (RAIU) differentiates high-uptake states (Graves) from low-uptake states (subacute/postpartum thyroiditis: uptake <1%–2%).

Pharmacotherapy: Methimazole vs. Propylthiouracil (PTU)

Thionamides inhibit thyroid peroxidase (TPO), blocking iodine organification and coupling.

Clinical Parameter Methimazole (MMI) Propylthiouracil (PTU)

Primary Indications Drug of choice in non-pregnant adults and 2nd/3rd trimesters of pregnancy. Drug of choice during 1st trimester of pregnancy, and in acute thyroid storm.

Mechanism of Action Inhibits TPO (iodine organification and coupling). Inhibits TPO AND blocks peripheral conversion of T4 to T3.

Gestational Teratogenicity Associated with Methimazole Embryopathy in 1st trimester: aplasia cutis congenita , choanal atresia , esophageal atresia. Lower teratogenic potential; acceptable during embryonic organogenesis.

Black Box Warning & Toxicity Agranulocytosis (fever/sore throat; check CBC stat); cholestatic jaundice. Black Box Warning for severe, idiosyncratic fulminant hepatotoxicity / acute liver failure .

Important

In women with Graves disease who become pregnant on methimazole, switch to PTU for the first trimester (or, if euthyroid on a low dose, consider stopping therapy with close monitoring). After the first trimester many clinicians return to methimazole to limit PTU hepatotoxicity, although the ATA notes the benefit of switching is uncertain.

Radioactive Iodine Ablation (I-131)

Radioactive iodine ablation destroys thyroid follicular cells. It is strictly contraindicated in pregnancy and lactation , as radioiodine crosses the placenta and destroys the fetal thyroid. Require a negative pregnancy test within 48 hours prior to administration and reliable contraception for at least 6 months post-treatment .

Postpartum Thyroiditis (PPT)

Postpartum thyroiditis is an autoimmune, destructive lymphocytic thyroiditis developing within the first 12 months postpartum . It occurs in roughly 5% to 10% of postpartum women, rising to 30% to 50% in women with positive anti-TPO antibodies or Type 1 diabetes.

The Triphasic Clinical Course

Phase 1: Hyperthyroid Phase (1 to 4 Months Postpartum; Duration: 2 to 8 Weeks): Autoimmune attack lyses follicles, releasing stored hormone into circulation. Radioactive iodine uptake is suppressed (<1%–2%). Symptoms include nervousness, palpitations, and heat intolerance.

Management: Thionamides (methimazole/PTU) are completely INEFFECTIVE because there is no excess hormone synthesis. Treat palpitations with beta-blockers (propranolol 20–40 mg PO TID) .

Phase 2: Hypothyroid Phase (4 to 8 Months Postpartum; Duration: Several Months): Depleted follicles fail to synthesize adequate hormone, leading to fatigue, lethargy, cold intolerance, weight retention, and impaired lactation. Frequently misdiagnosed as postpartum depression (PPD) ; screen serum TSH in all postpartum patients presenting with mood changes or fatigue. Treat with temporary levothyroxine for 6 to 12 months if symptomatic or TSH >10 mIU/L.

Phase 3: Recovery Phase (12 to 18 Months Postpartum): 70% to 80% experience spontaneous recovery and return to euthyroidism. However, 20% to 30% develop permanent overt hypothyroidism requiring lifelong levothyroxine, with >50% recurrence in subsequent pregnancies.